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Post-translational modifications (PTMs) of histones constitute a major chromatin indexing mechanism, and their proper
characterization is of highest biological importance. So far, PTM-specific antibodies have been the standard reagent for
studying histone PTMs despite caveats such as lot-to-lot variability of specificity and binding affinity. Herein, we suc-
cessfully employed naturally occurring and engineered histone modification interacting domains for detection and
identification of histone PTMs and ChIP-like enrichment of different types of chromatin. Our results demonstrate that
histone interacting domains are robust and highly specific reagents that can replace or complement histone modification
antibodies. These domains can be produced recombinantly in Escherichia coli at low cost and constant quality. Protein
design of reading domains allows for generation of novel specificities, addition of affinity tags, and preparation of PTM
binding pocket variants as matching negative controls, which is not possible with antibodies.
[Supplemental material is available for this article.]
The unstructured N-terminal tails of histones protrude from the
core nucleosome and harbor complex patterns of post-translational
modifications (PTMs) (Kouzarides 2007; Margueron and Reinberg
2010; Bannister and Kouzarides 2011; Tan et al. 2011). These PTMs
regulate a multitude of chromatin-templated transactions, play
a central role in development, and are implicated inmany diseases,
such as cancer (Suva et al. 2013). Therefore, understanding the role
of histone marks in chromatin-dependent processes is of para-
mount importance. So far, techniques based on the specific bind-
ing of antibodies to modified histone proteins have been the only
method available for genome-wide analyses of histone modifica-
tions with locus-specific resolution. The central role of antibodies
for the characterization of histone PTMs in chromatin research
makes the quality and reliability of these reagents a very important
scientific issue. In general, antibodies are very powerful and im-
portant reagents in biomolecular research, but the validation
of commercial antibodies is not always sufficiently rigorous
(Bordeaux et al. 2010). This is particularly important in the chro-
matin field, where specific recognition and discrimination of
subtle epitopes defined only by the presence of distinct PTMs is
required. Moreover, several important modifications occur in very
similar amino acid sequence motifs, like the methylation of H3K9
and H3K27, which are both placed in the context of an ARKS se-
quence. In addition, histone tails are hypermodified, as exempli-
fied by the H3 tail, where the adjacent R8, K9, and S10 amino acid
side chains are known to be methylated, acetylated, or phos-
phorylated. This implies that secondary modifications often occur
on the peptide segment contacted by the antibody in the imme-
diate vicinity of the target PTM and sometimes prevent the bind-
ing of antibodies in spite of the presence of the targetmodification,
yielding false negative results. When undocumented, the cross-
reactivity with related or unrelated marks and the combinatorial
effect of neighboring marks compromise the application of anti-
bodies, as illustrated in Figure 1. Additionally, different antibodies
show distinct profiles of false positive and false negative signals,
and even antibodieswith the same catalognumbers regularly show
lot-to-lot fluctuations of properties (also illustrated in Fig. 1). This
variability is not unexpected for polyclonal antibodies, where
new batches are produced by immunization of a new animal, but
changes of purification proceduremay cause variance of properties
of monoclonal antibodies as well. Occasionally some lots of com-
mercial antibodies even prefer to bind to secondary targets (see
Fig. 1 andH3K36me3 antibodies documented in Bock et al. 2011a).
This necessitates a detailed quality control and documentation of
each antibody and each lot in order to give the user all relevant
information for correct data interpretation, which is often not
sufficiently provided. The urgency for better quality assessment
and documentation of antibodies used in chromatin research has
been widely recognized in the field (Bock et al. 2011a; Egelhofer
et al. 2011; Fuchs et al. 2011; Nishikori et al. 2012; Peach et al.
2012; Hattori et al. 2013; Heubach et al. 2013), and the ENCODE
Project Consortium has set up quality criteria for histone PTM
antibodies (Egelhofer et al. 2011; Landt et al. 2012). According to
these guidelines, antibodies must specifically detect modified
histones in Western blots and fulfill one or more of the following
secondary criteria: (1) specific binding to modified peptides in dot
blot assays; (2) mass spectrometric detection of the modification
in precipitated chromatin; (3) loss of signal upon knockdown of
the corresponding histone modifying enzyme; (4) reproducibility
of ChIP-seq; (5) similarity of ChIP-seq results of two different
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antibodies directed against the samemodification; or (6) overlap of
ChIP-seq peaks with expected genomic annotations.
To develop an alternative to antibodies for chromatin re-
search,we assessed the applicative potential andutility of naturally
occurring and engineered histone modification interacting do-
mains (HMIDs). This approachhas several distinct advantages over
antibodies, such as the ease and cost-effectiveness of recombinant
production of HMIDs in Escherichia coli, the amenability of HMIDs
to protein engineering, and the possibility of producing them at
constant quality, eliminating lot-to-lot variability. In support of
this concept, affinity methods based on protein domains have
been successfully employed for the enrichment of methylated or
unmethylated CpG islands in the analysis of DNA methylation
(Cross et al. 1994; Blackledge et al. 2012) or in proteome-wide
analyses of non-histone lysinemethylation (Liu et al. 2013; Moore
et al. 2013). In this proof-of-principle study, we started by char-
acterizing the specificity of several HMIDs and compared them
with ENCODE-validated antibodies for the same PTM using pep-
tide arrays. Specificities were further validated in Western blots by
detecting histone tail PTMs using unmodified histones and his-
tones specifically depleted with the target PTM as controls. Then,
we investigated the applicative potential of HMIDs in ChIP-like
experiments to enrich for chromatin with particular modifica-
tions, which represents one of the most important and commonly
used applications of histone tail PTM antibodies.
Results
Specificity analysis of H3K9me3 binders on histone
peptide arrays
Histone PTMs exert their biological effects mainly through the
regulated binding of HMIDs, which are critical constituents of
many chromatin-modifying complexes (Taverna et al. 2007; Patel
andWang 2013). HMIDs are often small domainswith a stable fold
that can be easily expressed in E. coli and purified with high yield
by affinity chromatography (Supplemental Fig. 2A). Here, we
aimed to investigate the applicative potential of HMIDs as an
Figure 1. Peptide array analyses showing lot-to-lot fluctuations, cross-reactivity, and effects of proximal marks on the binding of popular histone tail
antibodies. Peptide spots are annotated on the left side of the glass slide. The color-coded boxes denote the presence of the designated modifications. (A)
Anti-H3K36me3 antibodies showed significant cross-reactivity to H4K20me1, H4K20me3, H3K27me3, H3K9me3, and H3K36me2. All lots of the
H3K36me3 antibody had a weak binding specificity, and they showed very different properties. (B) Anti-H3K9me3 antibodies displayed cross-reactivity to
H3K27me3 (Lot 3 even prefers H3K27me3 peptides) and H4K20me3 (very overt in the case of Lot 1 and Lot 4). H3K9me3 peptide spots that were not
bound by these antibodies generally also contained H3S10ph or H3T11ph, indicating that this secondary mark prevents binding. For a more detailed
annotation of the modifications at each spot, refer to Supplemental File S2. Among the H3K9me3 antibodies, only Lot 2 showed a binding specificity of
acceptable quality. Anti-H3K36me3 (Lot 1) and anti-H3K9me3 (Lot 1) data were taken from Bock et al. (2011a) and reprocessed. Additional examples of
commercial H3K36me3 antibodies with insufficient specificity are shown in Bock et al. (2011a). Examples of the fundamental differences in the specificity
profiles of different antibodies directed against H3K27me3 are given in Supplemental Figure S1.
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alternative to histone PTM-specific antibodies. Specific binding to
modified peptide epitopes is a necessary prerequisite for histone
PTM antibodies and HMIDs (Egelhofer et al. 2011; Landt et al.
2012). In order to obtain detailed information about the specificity
of histone PTM antibodies and HMIDs, it is essential to test their
binding to a large collection of potential substrate peptides with
various combinations of PTMs. Such experiments can be ideally
conducted using peptide arrays. We used the CelluSpots histone
peptide arrays, which feature 384 peptides and 59 identified or
hypothetical histone PTMs of all histone tails (Dhayalan et al.
2010, 2011; Zhang et al. 2010; Bock et al. 2011a,b). Each glass slide
contains two copies of the same array to ensure reliability. As a first
step toward comparing the properties of histone PTM antibodies
andHMIDs,we conducted a direct side-by-side comparison of the
CelluSpots binding patterns of the MPHOSPH8 (also known as
MPP8) Chromo and ATRX ADD domains, which are well-charac-
terized H3K9me3 binders (Bock et al. 2011a; Dhayalan et al. 2011;
Li et al. 2011), and different batches of a widely used and ENCODE-
validated anti-H3K9me3 antibody (Figs. 1, 2A). The H3K9me3
mark was selected because it is among the most widely studied
histone PTMs.
The MPHOSPH8 Chromo domain binds specifically to his-
tone H3 trimethylated on lysine 9 through the same conserved
recognition mechanism as the Chromo domains of the HP1 pro-
tein family (including human CBX1) (Li et al. 2011). On the pep-
tide array, MPHOSPH8 Chromo bound most prominently
to H3K9me3 peptides and to a lesser extent to H3K9me2 and
H3K27me3peptides (Fig. 2A; Bock et al. 2011b). Akin to theChromo
domain of CBX1 (Supplemental Fig. S3A), peptide binding was
inhibited by adjacent H3S10ph and H3T11ph, but not by H3R8citr.
The observed weak binding to H3K27me3 is discordant with so-
lution peptide binding studies, where binding to H3K27me3 was
undetectable (Li et al. 2011). The ATRX ADD domain exhibited
strong binding to peptides harboring H3K9me3 and weaker to
peptides having H3K9me2 (Fig. 2A). The bindingwas abrogated by
secondary modifications at the H3K4 position and H3S10ph or
H3T11ph. These observations are in agreement with previous data
where the dual readout of unmodified H3K4 and trimethylated
H3K9 by the ATRX ADD domain was reported (Dhayalan et al.
2011; Eustermann et al. 2011; Iwase et al. 2011). Themodification-
dependent interaction of MPHOSPH8 Chromo and ATRX ADD
with histone peptides was confirmed with methyllysine-binding
pocket mutants, which all lost peptide binding (Supplemental
Fig. S4A). The best lot of the Abcam ab8898 anti-H3K9me3 anti-
body (Lot 2) bound specifically to H3K9me3 modified peptides
with a minute cross-reactivity to H3K27me3 and H4K20me3
(Fig. 1). Similarly to MPHOSPH8 Chromo, ATRX ADD and other
commercial anti-H3K9me3 antibodies (Bock et al. 2011a) phos-
phorylation of S10 or T11 eliminated binding. We conclude that
the specificity of MPHOSPH8 Chromo and ATRX ADD is compa-
rable to good antibodies currently used in chromatin research, and
the ENCODE criterion for specific binding to peptide epitopes is
fulfilled by these HMIDs.
Western blot analyses of H3K9me3 binders
To further test the applicative potential of HMIDs as detection and
affinity precipitation reagents, Western blot experiments were
carried out in which an HMID was used instead of a primary an-
tibody. This experiment allows investigation of the specificity of
Figure 2. Peptide array and Western blot specificity analyses of H3K9me3-specific reagents. (A) CelluSpots peptide array analyses of ATRX ADD and
MPHOSPH8 Chromo. Peptide spots are annotated on the left side of the glass slide. The color-coded boxes denote the presence of the designated
modifications. ATRX ADD did not bind to H3K9me2/3 peptides also containing H3K4me2/3, H310Sph, or H3T11ph. Binding of MPHOSPH8 Chromo to
peptides containing H3K9me2/3 or H3K27me3 was inhibited by H3S10ph, H3T11ph, or H3S28ph. For amore detailed annotation of themodifications at
each spot, refer to Supplemental File S2. For comparison with anti-H3K9me3 antibodies, refer to Figure 1. The MPHOSPH8 data set was taken from Bock
et al. (2011b) and reprocessed. (B) Western blot analysis using ATRX ADD,MPHOSPH8Chromo, and anti-H3K9me3 antibody (Lot 2) with native (NH) and
recombinant histones (RH). The approximate position of the H3 protein at 15 kDa is indicated. (C ) Western blot (WB) analysis using ATRX ADD,
MPHOSPH8 Chromo, and the same anti-H3K9me3 antibody with nucleosomes isolated from wild-type and Suv39h1 and Suv39h2 double knockout
(DKO) cells. The Coomassie brilliant blue (CBB)-stained gel after transfer is shown as a loading control.
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HMID binding, as well as cross-reactivity with other histone PTMs
and nuclear proteins. MPHOSPH8 Chromo and ATRX ADD do-
mains performed robustly as Western blot detection reagents by
specifically binding to native histones prepared from human cell
lines, but not to recombinant histones, which do not carry PTMs
(Fig. 2B). In each case, themodification-dependent interactionwas
confirmed with methyllysine-binding pocket mutants, which lost
binding (Supplemental Fig. S4B). To further verify the specificity of
the interaction with H3K9me3, Western blot experiments were
carried out with histones isolated from wild-type and Suv39h1/
Suv39h2 double-knockout (DKO) immortalizedMEF cells (Fig. 2C).
With both MPHOSPH8 Chromo and ATRX ADD, the binding to
DKO histones was reduced to a similar extent as observed with the
corresponding antibody. Next, to address the minute cross-re-
activity of MPHOSPH8 Chromo to H3K27me3 peptides on the
peptide array, we performedWestern blot experiments against cells
treated with an EZH2 inhibitor (Fiskus et al. 2009), which leads to
a strong reduction of global H3K27me3 (Fig. 5B, see below). No
reduction of H3 interaction was observed (Supplemental Fig.
S4C), which confirms that MPHOSPH8Chromo does not bindH3
harboring H3K27me3 (Li et al. 2011). Based on the specificity and
Western blot data, we conclude that MPHOSPH8 Chromo and
ATRXADDdomains are as specific as antibodies and can be utilized
as a powerful and specific readout tool in Western blot assays.
Chromatin precipitation analyses using H3K9me3 binders
Next, we investigated if HMIDs have the ability to specifically
precipitate discrete types of chromatin containing the target mod-
ifications in native ChIP-like assays, which represents one of the
most important applications of histone PTM antibodies. We call
these experiments chromatin interacting domain precipitation
(CIDOP). The chromatin used in these experiments was prepared
from HepG2 cells and consisted primarily of mononucleosomes
(Supplemental Fig. S2B). CIDOP and ChIP were conducted with
HMIDs and antibodies in parallel. Initially, the recovered DNAwas
analyzed by quantitative PCR of selected loci containing defined
PTMs based on ENCODE ChIP-seq data of HepG2 cells (The
ENCODE Project Consortium 2011). As shown in Figure 3A, the
CIDOP-qPCR profiles of MPHOSPH8 Chromo and ATRX ADD are
in very good agreement with the corresponding anti-H3K9me3
antibody (Lot 2), although the domains show a slightly higher
signal for nontargets than the antibody. The precipitation of
chromatin was modification-dependent, as indicated by experi-
ments carried out with the methyllysine-binding pocket mutants,
where no pull down was observed (Supplemental Fig. S4D).
To extend theCIDOP-qPCR results to a genome-wide level, we
performed chromatin interacting domain precipitation coupled
with next-generation sequencing (CIDOP-seq). We compared our
CIDOP-seq data with available ENCODE ChIP-seq data from
HepG2 cells (Fig. 3B). It is worth pointing out that optimal stan-
dards for comparison and detection of broad marks such as
H3K9me3, H3K27me3 and H3K36me3 are lacking or being de-
veloped (Landt et al. 2012). Identical data analysis procedures were
used for CIDOP and ChIP experiments in our study. We compared
peak regions obtained with ATRX ADD,MPHOSPH8 Chromo, and
the anti-H3K9me3 antibody and observed a notable overlap (Fig.
3C), aswell ashigh Spearman correlation coefficients of tags in 15-kb
bins (Fig. 3D). The correlation of biological CIDOP-seq replicates
was similar to typical ChIP-seq replicates (Supplemental Fig. S7A,
B). As expected, the majority of peak regions were enriched in
heterochromatin in all three experiments (Supplemental Fig. S4E),
which reflects the known heterochromatic localization of
H3K9me3 (Peters et al. 2001, 2002). Also, the distribution of peak
regions among different genomic elements was very similar in all
three experiments, with the majority of peak regions localizing in
distal intergenic sites (Fig. 3E). We analyzed the distribution of
peak regions in repeat elements, again yielding similar results
(Fig. 3F). The strong similarity of ATRX ADD, MPHOSPH8 Chromo,
and anti-H3K9me3 antibody binding profiles and the difference
compared to H3K9me2 and H3K27me3 profiles (Supplemental
Fig. S8A,C,D) indicates that HMIDs are as efficient in genome-wide
chromatin studies as good antibodies.
Since the ATRXADDdomain simultaneously reads the absence
of di- and trimethylation at H3K4 and the presence of H3K9me3,
while MPHOSPH8 Chromo and the antibody only recognize
H3K9me3, the coexistence of H3K4me2/3 and H3K9me3 on one
H3 tail would result in loss of signal in ATRX ADD precipitated
chromatin, while MPHOSPH8 Chromo and anti-H3K9me3 anti-
body should remain unchanged. As mentioned above, the ATRX
ADD, MPHOSPH8 Chromo, and anti-H3K9me3 antibody binding
profiles were very similar, indicating that such coexistence of
H3K4me2/3 and H3K9me3 on one tail must be rare. To detect
potential minor fractions of chromatin containing this double
modification, we performed k-means clustering of the CIDOP-seq
and ChIP-seq data, which allows for the detection of small sub-
groups of potentially biologically relevant loci. We did not observe
prominent differences in the formation of clusters between ATRX
ADD, MPHOSPH8 Chromo, and anti-H3K9me3, and the vast ma-
jority of clusters were depleted of H3K4me3methylation (Fig. 3G),
even when we extended the number of clusters to one hundred or
aligned the reads around the TSS (Supplemental Data S4F,G). These
results indicate that H3K9me3 and H3K4me2/3 do not or rarely
coexist on the same histone tail, which is consistent with previous
reports, where lack of correlation betweenH3K9me3 andH3K4me3
in global distribution profiles was observed (Barski et al. 2007).
Application of the DNMT3A PWWP domain as H3K36me3
binder
Since anti-H3K36me3 antibodies often showed weak specificity
(see Fig. 1 and Bock et al. 2011a), novel tools for detection and
enrichment of H3K36me3 marks are needed. For that reason, we
decided to investigate the applicability of the DNMT3A PWWP
domain, which has modest affinity to methylated H3K36 in vitro
(Dhayalan et al. 2010; Bock et al. 2011a), as a reagent in chromatin
research. On the peptide array, the PWWP domain of DNMT3A
specifically bound to H3K36me2 and H3K36me3 peptides, and no
other interaction was detected, while a popular anti-H3K36me3
antibody (Abcam, ab9050) displayed binding to H3K36me2/3, but
also cross-reactivity to H3K27me3, H3K9me3, H4K20me, and
H4K20me3 peptides (Figs. 1, 4A). The CelluSpots array contains
only one H3K36me3 peptide spot, precluding an analysis of the
potential effects of proximal marks. In Western blot experiments,
the PWWP domain bound to native but not to recombinant his-
tones, fulfilling the corresponding ENCODE quality criteria (Fig.
4B). Native histones isolated from wild-type and set2 knockout
Saccharomyces cerevisiae cells were successfully used to validate the
specificity of the interaction (Fig. 4C). However, with this experi-
ment we were not able to address the cross-reactivity of the anti-
H3K36me3 antibody with H3K27me3 and H4K20me3, due to the
absence of these marks in S. cerevisiae. These promising results
prompted us to conduct chromatin precipitation experiments
with the PWWP domain as well. The precipitation of chromatin
Application of HMIDs as an alternative to antibodies
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Figure 3. CIDOP and ChIP of ATRX ADD, MPHOSPH8 Chromo, and anti-H3K9me3 antibody. (A) Comparison of CIDOP-qPCR and ChIP-qPCR signals
with domains and anti-H3K9me3 antibody (Lot 2 from Fig. 1) using amplicons associated with H3K9me3, H3K27me3, H3K4me3, and H3K36me3. All
experiments were carried out in triplicates of biological duplicates. Error bars represent the standard errors of the mean. (B) Representative genome
browser snapshot comparing CIDOP-seq andChIP-seq signals of domains and anti-H3K9me3 antibody (taken from ENCODE). Formore examples, refer to
Supplemental Figures S7A, S8A, and S8C. (C ) Venn diagram of the overlap of peak regions between domains and anti-H3K9me3 antibody. The number of
peaks in each area is given in Supplemental Table S3. (D) Spearman correlation coefficient heatmap of CIDOP-seq and ChIP-seq tags in 15-kb bins. (E )
Distribution of CIDOP-seq and ChIP-seq peaks among different genomic elements. (F) Distribution of CIDOP-seq and ChIP-seq peaks among different
repeat elements (cf. Supplemental Fig. S4E). (G) Clustering analysis of tag densities from MPHOSPH8 Chromo and ATRX ADD CIDOP-seq as well as anti-
H3K9me3 and H3K4me3 antibody ChIP-seq data sets. Tags were collected within a 20-kb window, centered on themidpoints of anti-H3K9me3 antibody
peaks, and sorted by k-means clustering (30 clusters). An analysis with 100 clusters is shown in Supplemental Figure S4F.
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Figure 4. Comparative analysis of results obtained with the DNMT3A PWWP domain and anti-H3K36me3 antibody. (A) Peptide array analysis of the
specificity of DNMT3A PWWP. For comparison with anti-H3K36me3 antibodies, refer to Figure 1. (B) Western blot analysis using DNMT3A PWWP and
anti-H3K36me3 antibody (Lot 2 from Fig. 1) with native (NH) and recombinant histones (RH). (C ) Western blot (WB) analysis using DNMT3A PWWP and
anti-H3K36me3 antibody (Lot 3 from Fig. 1) with native histones isolated from wild-type and set2 KO S. cerevisiae. The Coomassie brilliant blue (CBB)-
stained gel after transfer is shown as a loading control. (D) Comparison of CIDOP-qPCR and ChIP-qPCR results obtained with the DNMT3A PWWP domain
and anti-H3K36me3 antibody (Lot 2) using amplicons associated with H3K27me3, H3K9me3, and the gene bodies of VEGFA and PABPC1. All experiments
were carried out in triplicates of biological duplicates. Error bars represent the standard errors of the mean. (E) Representative genome browser snapshot
comparing CIDOP-seq and ChIP-seq results obtained with the DNMT3A PWWP domain and anti-H3K36me3 antibody (ENCODE). For more examples,
refer to Supplemental Figure S10. (F ) Venn diagram of the overlap of peak regions between DNMT3A PWWP domain and anti-H3K36me3 antibody. (G)
Spearman correlation coefficient heatmap of CIDOP-seq and ChIP-seq tags in 15-kb bins. (H) Metagene profiles of DNMT3A PWWP and anti-H3K36me3
antibody ranked by differential expression. The shaded lines represent the standard errors of the mean. Supplemental Figure S5D shows this image with
the y-axis scale starting from 0. (I ) Clustering analysis of tag densities from the DNMT3A PWWP and anti-H3K36me3 antibody CIDOP-seq and ChIP-seq
data sets. Tags were collected within a 10-kb window around TSS and sorted by k-means clustering (50 clusters). The clusters with low DNMT3A PWWP
and anti-H3K36me3 signals also lack H3K4me3 and likely are not expressed (not shown).
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was modification-dependent, as indicated by experiments carried
out with the PWWP methyllysine-binding pocket variant (Sup-
plemental Fig. S5). CIDOP-qPCR and CIDOP-seq data resembled
but were not fully identical to the corresponding ChIP-qPCR
(H3K36me3 antibody Lot 2) and ChIP-seq data (ENCODE anti-
body) (Fig. 4D,E,G–I; Supplemental Fig. S10). The CIDOP-qPCR
and ChIP-qPCR experiments (Fig. 4D) showed enrichment of sig-
nal in gene bodies as exemplified at the VEGFA and PABPC1 loci,
although the individual intensities slightly differed. In addition,
the recovery with PWWP was lower than with antibody, which
may be related to the lower binding affinity of PWWP. Furthermore,
in the anti-H3K36me3 antibody experiment, we observed enrich-
ment of satellite alpha, which is likely due to the cross-reactivity of
the antibody with H4K20me3. Next, we conducted CIDOP-seq
and compared with ChIP-seq data obtained with H3K36me3 anti-
body and observed a clear overlap of peaks and high correlation
coefficients of both data sets (Fig. 4F,G). The correlation between
the PWWP domain and the anti-H3K36me3 antibody was similar
to biological replicates of anti-H3K36me3 antibodies (Supple-
mental Fig. S7D). Genome browser snapshots verified the clear
colocalization of signals (Fig. 4E; Supplemental Fig. S10), which
was also observed in a metagene analysis and k-means clustering
around transcription start sites (Fig. 4H,I). Both signals were cor-
related with the level of gene expression (Fig. 4H). As in the
CIDOP-qPCR experiments, a slight difference in the distribution of
intragenic signals between the domain and the antibody was ob-
served, inwhich the domain tends to enrich signals in the 59 end of
genes, while the antibody signals are more enriched in the middle
and 39 part of genes. However, wewant to raise caution by pointing
out the insufficient specificity of the H3K36me3 antibodies (see
Fig. 1 and Bock et al. 2011a). Therefore, some of the signals
obtained by H3K36me3 ChIP experiments could result from an
off-target binding of the anti-H3K36me3 antibody, as illustrated by
the detection of satellite alpha signal.
Application of the CBX7 Chromo domain as H3K27me3
binder
Finally, we investigated the applicability of the CBX7 Chromo
domain as a potential reader of H3K27me3, because H3K27me3,
like H3K9me3, is a widely studied chromatin PTM. CBX7 is
a component of the Polycomb repressive complex 1 (PRC1) known
to bind to H3K27me3. In spite of this, its Chromo domain was
reported to bind indiscriminately to H3K27me3 and H3K9me3
on peptide arrays (Kaustov et al. 2011). Accordingly, we observed
binding of CBX7 Chromo to both H3K27me3- and H3K9me3-
containing peptides on the CelluSpots arrays, showing sensitivity
to neighboring H3R26citr and H3S28ph (Supplemental Fig. S6).
The H3K27me3 antibody (No.1 Lot 1) specifically bound to
H3K27me3 peptides, and binding was abolished by adjacent
H3S28ph marks (Supplemental Fig. S1). The CBX7 Chromo do-
main performed robustly inWestern blot experiments (Fig. 5A). To
determine its specificity in histone binding, we conducted exper-
iments with histones isolated from wild-type and Suv39h DKO
immortalized MEF cells and HepG2 cells treated with an EZH2
inhibitor and compared the results with anti-H3K9me3 and anti-
H3K27me3 antibodies. As shown in Figure 5, B and C, CBX7
binding was lost after EZH2 inhibition, but it bound equally to
histones isolated from wild-type and Suv39hDKO cells, indicating
a specific readout of H3K27me3 by CBX7 Chromo. This observa-
tion was further validated with CIDOP-qPCR/CIDOP-seq and the
corresponding ChIP-qPCR/ChIP-seq experiments, where the CBX7
Chromo domain displayed a clear mono-specific precipitation of
H3K27me3-associated chromatin (Fig. 5D,E; Supplemental Figs.
S8C,D, 9). A notable overlap of the peak regions of CBX7 Chromo
and anti-H3K27me3 antibodywas observed, but not with the anti-
H3K9me3 antibody (Fig. 5F; Supplemental Fig. S8E). Furthermore,
we observed a high Spearman correlation of the domain data with
the anti-H3K27me3 antibody in 10-kb bins (Fig. 5G) as one would
typically expect in ChIP-seq of biological replicates (Supplemental
Fig. S7C), suggesting that the binding to H3K9me3 only occurs
with peptides. It is likely that CBX7 Chromo requires a longer part
of the histone tail for specific H3K27me3 recognition than the one
present on the peptide arrays. The modification-dependent in-
teraction of CBX7 Chromo with histones was verified with
a methyllysine-binding pocket mutant (Supplemental Data S6).
Finally, ametagene analysis of CBX7Chromo and anti-H3K27me3
antibody as expected showed a higher enrichment of signal for
PRC2-associated genes, compared to expressed genes in HepG2 or
all annotated genes (Fig. 5H), again indicating the similarity be-
tween the two reagents.
Discussion
Chromatin is a highly dynamic and multifaceted structure
embellished with more than 150 histone PTMs (Kouzarides 2007;
Margueron and Reinberg 2010; Bannister and Kouzarides 2011;
Tan et al. 2011). Chromatin precipitation studies with antibodies
have been the workhorse of chromatin biology in deciphering the
complex syntax of the histone modification language. However,
these are indirect experiments, and the identity of the material
captured in these studies fully depends on the reagent. As docu-
mented above, the properties and specificity reports of existing
antibodies are imperfect, so that novel analytic tools are necessary.
To this aim, we have developed a collection of native and engi-
neered histone modification interaction domains (HMIDs), which
strongly and specifically interact with H3 tails methylated at dif-
ferent lysine residues. The most promising domains were inves-
tigatedwith respect to the primary and secondary ENCODE criteria
for antibody validation, such as specificity in Western blotting
with native, recombinant, and PTM-depleted histones, binding
to modified peptides, and ChIP-like experiments (Egelhofer
et al. 2011; Landt et al. 2012). In all our experiments, the effi-
ciency of HMIDs was directly compared side-by-side with popular
commercial antibodies recognizing the same PTMs. Our results
show that HMIDs fulfill all tested antibody quality criteria. Most
importantly, the comparative analyses of HMIDs and ENCODE
validated antibodies inCIDOP andChIP experiments showedhigh
correlation of signals, indicating the potential of using HMIDs
alone or in concert with antibodies in genome-wide or locus-
specific studies.
HMIDs bind strong enough to modified histone tails
for applications in chromatin biology
One obvious difference between antibodies and HMIDs is in their
binding affinity to modified histone tails. The KD values of HMIDs
used here are in the high nanomolar to low micromolar range
(MPHOSPH8 Chromo binding to H3K9me3 peptides: 120 nM
[Bock et al. 2011a], 140 nM [Chang et al. 2011]; ATRX ADD-
H3K9me3: 1.4 mM [Dhayalan et al. 2011]; DNMT3A PWWP-
H3K36me3: 64 mM [Dhayalan et al. 2010]; CBX7-H3K27me3:
22 mM [Bernstein et al. 2006]). In contrast, typical antibody bind-
ing constants of commercial histone tail antibodies are in the low
1848 Genome Research
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nanomolar to low micromolar range (for example, two papers
reported KD values of 0.2, 4, 60, 83, 520, 820, 1000, 2200, and 2700
nM for several representative commercial antibodies [Nishikori
et al. 2012; Hattori et al. 2013]). As indicated by these numbers, the
ranges of affinities of antibodies and HMIDs overlap, but in gen-
eral, antibodies bind more strongly. However, the specificity of
a reagent is defined by the ratio of the specific and nonspecific
interaction, so that the absolute binding affinity does not play
Figure 5. Comparative analysis of results obtained with the CBX7 Chromo domain and anti-H3K27me3 antibody No. 1 Lot 1 (Supplemental Fig. S1).
(A) Western blot analysis of CBX7 Chromo and anti-H3K27me3 antibody binding to native (NH) and recombinant histones (RH). (B) Western blot analysis
of CBX7 Chromo and anti-H3K27me3 antibody binding to nucleosomes isolated from EZH2 inhibitor (DZNep)- or DMSO-treated HepG2 cells. (C )
Western blot analysis of CBX7Chromo and anti-H3K27me3 antibody binding to histones isolated fromwild-type and Suv39hDKO immortalizedMEFs. (D)
Comparison of the CIDOP-qPCR and ChIP-qPCR results of the CBX7 Chromo domain and anti-H3K27me3 antibody analyzed with amplicons associated
with H3K27me3, H3K9me3, and H3K36me3. All experiments were carried out in triplicates of biological duplicates. Error bars represent the standard
errors of the mean. (E) Representative genome browser snapshot of CIDOP-seq and ChIP-seq data obtained with the CBX7 Chromo domain and anti-
H3K27me3 antibody (taken from ENCODE). For more examples, refer to Supplemental Figures S8C and S9. (F ) Venn diagram of the overlap of peak
regions between CBX7 Chromo domain and anti-H3K27me3 antibody. (G) Spearman correlation coefficient heatmap of CIDOP-seq and ChIP-seq tags in
10-kb bins. (H) Metagene profiles of CBX7 Chromo and anti-H3K27me3 antibody ranked by association with all genes, all expressed genes, and PRC2
(EZH2)-associated genes. The shaded lines represent the standard errors of the mean.
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a major role. The weaker equilibrium binding affinity of HMIDs
may lead to lower fractional saturation of histone proteins with
HMIDs as compared with antibodies, but this can be compen-
sated by higher concentrations of these reagents in the experi-
ment. Since all typical chromatin assays are heterophasic, the
half-life of HMID or antibody complexes with peptides or histone
proteins (as determined by the kinetic dissociation constant of
the complex, koff) is another critical parameter. In this study we
show experimentally that HMIDs also satisfy the applicative
needs in this respect.
Strengths and pitfalls of first principle techniques for antibody
and HMID specificity validation
There are two main hypothesis-free approaches to determine the
binding specificity of histone tail interacting reagents—mass spec-
trometry and binding to modified peptides. Mass spectrometry is
the only method allowing the study of the nature of the chromatin
captured by a binding reagent directly. It is among the secondary
criteria for quality control of antibodies suggested by the ENCODE
Project Consortium. Currently, mass spectrometry is especially use-
ful in the specificity analysis of antibodies for DNA interacting
proteins, but less powerful for the analysis of histone PTM anti-
bodies (Landt et al. 2012). The reason for this is that precipitation
of one chromatin modification can simultaneously enrich associ-
ated secondary modifications on the same histone tail or on the
same nucleosome. Since mass spectrometry cannot pinpoint the
direct interaction of an antibody and a target modification, it is
impossible to decide if coenrichment of a secondary modification
is due to a cross-reactivity of the reagent or if the secondarymark is
associated with the primary target. In addition, the identification
of inhibitory secondary marks is difficult by mass spectrometry.
However, future technological improvementsmay further increase
the value of mass spectrometric analysis for histone PTM antibody
and HMID quality assessment.
The second approach allowing for a directed determination
of the specificity of histone tail interacting reagents is to in-
vestigate their binding to modified peptides. For a detailed anal-
ysis, modified histone tail peptide arrays are particularly powerful,
since they contain a lot of histone tail peptides with different PTMs
in different combinations. Hence, they allow for cross-reactivity
analyses of histone binding reagents and detection of inhibitory
effects of secondary modifications (Bock et al. 2011a). However,
our data also illustrate some pitfalls of peptide-based specificity
analysis of histone PTM binders, because even antibodies and
HMIDs, which show some cross-reactivity with peptides, can still
give clear-cut ChIP and CIDOP profiles. For example, the cross-
reactivities of MPHOSPH8 Chromo toward H3K27me3 peptides
and CBX7 Chromo toward H3K9me3 peptides were not detect-
able in chromatin experiments. Differences between peptide
and histone binding of antibodies and HMIDs may be due to the
fact that peptides are too short, which may lead to more
promiscuous binding because HMIDs may form additional in-
teractions to the histone outside of the peptide region. Moreover,
peptides present artificial ends when compared to histone pro-
teins, which, for example, may allow an H3K9me3 binder to in-
teract with an H3K27me3 peptide, but not with the K27me3
modified histone H3 protein. However, modified peptides are one
of the few ways to define the detailed specificity profile of an an-
tibody or HMID by first principle. Hence peptide binding, in our
view, will remain an important reference pointwhen analyzing the
specificity of these reagents.
HMIDs can be produced at constant quality with invariable
properties
Collectively, our data show compelling evidence that HMIDs are
powerful and versatile affinity and detection reagents that hold
a genuine applicative potential. Like antibodies, these domains do
show some cross-reactivity and dependence on secondary modi-
fications. However, the recombinant expression and easy purifi-
cation of HMIDs will allow for production of HMIDs at a constant
quality, eliminating lot-to-lot variability. Therefore, detailed
specificity documentation of an HMID, including data on cross-
reactivity and the combinatorial effects of secondary modifica-
tions, once prepared, will be valid for all future lots of this reagent.
The availability of detailed specificity documentationwill allow for
more reliable interpretation of gain and loss of signals in genome-
wide and locus-specific chromatin studies. In addition, the un-
limited availability of HMIDswith invariable properties will enable
researchers to directly compare results obtained in different labs
and reproduce data much more easily. Thereby, the application of
HMIDswill improve the overall scientific quality and stringency in
the field. This point is illustrated by the fact that we were unable to
directly investigate the quality and cross-specificity of the partic-
ular antibody lots used by the ENCODE labs for ChIP-seq, because
these lotswere no longer available. Such problemswould not occur
with HMIDs, which can be produced with constant quality and
invariable properties. Recently, recombinant antibodies have been
described that also have the potential to solve the problem of lot-
to-lot variability (Hattori et al. 2013), but they are much more
difficult to generate than HMIDs. After submission of our work,
another publication also raised concerns about histone PTM
antibody quality and demonstrated the application of reading
domains for the analysis of chromatin states (Su et al. 2014).
However, the Su et al. (2014) work was not based on a systematic
validation of HMIDs and side-by-side comparison with antibodies
following ENCODE guidelines.
Potential limitations of the antibody- and HMID-based
technologies
In spite of the fact that quality control measures will continue to
evolve, along with novel domain-based technologies and more
stringent antibody production conditions, the presence of hyper-
modified histone tails with similar amino acid sequences carrying
chemically related PTMs might impose tight limits on the maxi-
mum specificity that can be obtained with these histone inter-
acting reagents. Using HMIDs might alleviate this problem by
providing detailed specificity documentation of each and every
precipitation domain, such that researchers can decide if the
properties of a certain domain will match its planned application.
Further perspectives of the HMID technology
In addition to providing a reliable and cost-effective experimental
tool, HMIDs could openmany novel research avenues due to their
ease ofmanipulation and amenability to protein engineering. This
allows for adding affinity tags for simplified detection, preparation
of PTM binding pocket variants as ideal matching negative con-
trols (as exemplified in this work), and design of novel specificities.
For example, we show here that the di- and trimethyl pan-specific
binding of the KDM4A double Tudor domain can be changed ei-
ther to a trimethyl pan-specific or to an H4K20me2/3monospecific
readout (Supplemental Fig. S11). Along the same lines, the S10ph
inhibition of H3K9me3 binders could be resolved by rationally
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designed or naturally occurring phosphorylation-insensitive
H3K9me3 HMIDs (Rothbart et al. 2012). Additionally, there is an
increased interest in the readout of complex histone PTMpatterns.
The differential readout of H3K9me3 in the context of modified or
unmodified H3K4 tails by different HMIDs enabled us here to di-
rectly demonstrate that there is none or little coexistence of
H3K9me3 and H3K4me2/3 on single H3 tails. In the future, it is
even conceivable to design fusion domains with dual specificities
for different marks, which in principle is not possible with anti-
bodies. For instance, a combined readout of H3K9me3 and
H4K20me3 may be used to probe the heterochromatic landscape
and reveal the extent of codependency between these two marks.
On the same note, the combined readout of H3K27me3 and
H3K4me3 could assist the investigation of bivalent domains. We
anticipate that HMID-based novel experimental tools will aid
the community in answering important questions in chromatin
biology.
Methods
Cloning, site-directed mutagenesis, expression, and purification
The sequences encoding the Chromo domain of human CBX7
(amino acids 7–61 of Swiss-Prot entry O95931), CBX1 (also known
as HP1beta homolog) (17–76 of NP_001120700.1), MPHOSPH8
(also known asMPP8) (57–111 of NP_059990.2), the double Tudor
domain of human KDM4A (also known as JMJD2A) (856–1047
NP_055478.2), the ADD domain of human ATRX (163–292 of
NP_000480.2), and PWWP domain of murine DNMT3A (279–420
of NP_001258682) were amplified from cDNA and cloned as GST-
fusion proteins into the pGEX-6p-2 vector (GE Healthcare). The
sequences of the expression vectors are given in Supplemental File
S3. All GST-tagged proteins were overexpressed at 18°C and puri-
fied essentially as described in Rathert et al. (2008), electro-
phoresed on 12% SDS-PAGE, and stainedwith colloidal Coomassie
brilliant blue G-250. Mutations were introduced using the mega-
primer method described in Jeltsch and Lanio (2002), and suc-
cessful mutagenesis was confirmed by restriction analysis and
Sanger DNA sequencing.
Cell culture
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium
with 5% fetal bovine serum at 37°C at 5% CO2 until they reached
90% confluence. HepG2 cells were grown in Dulbecco’s modified
Eagle’s medium with 10% fetal bovine serum at 37°C and 5% CO2
until they reached 75% confluence. When necessary, the HepG2
cells were supplemented with 1 mM DZNep (Calbiochem, EMD
Millipore) (Fiskus et al. 2009) for 72–96 h, collected, and processed.
Immortalized MEFs were grown in DMEM supplemented with
10% FBS, L-glutamine, nonessential amino acids, sodium pyru-
vate, and 100 mM b-mercaptoethanol.
Binding of domains and antibodies on CelluSpots histone
peptide arrays, Western blot, and peptide pull down
Experiments to determine the binding specificity and context
dependence of the GST-fusion domains and antibodies were per-
formed using the CelluSpots peptide array platform as described in
Bock et al. (2011a,b). Popular antibodies (although not the same
batches) were selected from the Antibody Validation Database
(http://compbio.med.harvard.edu/antibodies). In this study, we
used anti-H3K27me3 antibody (Active Motif, #39155), anti-
H3K9me3 (Abcam, ab8898), anti-H3K36me3 (Abcam, ab9050),
and H3K9me2 (Abcam, ab1220). The lots of the corresponding
antibodies are specified in Supplemental Table S2. For Western
blots, we applied the peptide array protocol. Native histones were
isolated by acid extraction (Shechter et al. 2007) from HEK293
cells or S. cerevisiae grown in YPD medium overnight (after sphe-
roplasting and extensive nuclei preparation), and recombinant
histones H3 and H4 were purchased from New England Biolabs or
purified from E. coli. Five micrograms of native histones and 2.5 mg
of recombinant histones were loaded and electrophoresed on 16%
SDS-PAGE and transferred onto nitrocellulose membranes. The
amounts of GST-fused proteins (wild type and mutants) used in
CelluSpots and Western blot analyses were the following: CBX7
Chromo (10–100 nM), CBX1 Chromo (10 nM), MPHOSPH8
Chromo (10–100 nM), KDM4A double Tudor (10 nM), ATRX ADD
(10 nM) (for WB binding in 300 mM NaCl peptide array buffer),
andDNMT3APWWP (10–100nM). The antibodies were incubated
following the manufacturer’s recommendations. All experiments
were performed in duplicates or triplicates. Pull-down experiments
with biotinylated peptides were performed as described in Kim
et al. (2006).
Native chromatin precipitation (CIDOP and ChIP)
and quantitative PCR
Native nucleosomes were isolated from around 20 million HepG2
cells (which was sufficient for 5–15 CIDOP/ChIP experiments) by
micrococcal nuclease digestion of nuclei as described (Brand et al.
2008) with minor modifications. In brief, following MNase di-
gestion, the nuclei were centrifuged at 13,000g for 10min, and the
resulting supernatant which contained the soluble nucleosomal
fraction (predominantly mononucleosomes) was collected and
snap frozen. Then, native chromatin (7.5–60 mg based on DNA
absorbance) was precleared for 1 h at 4°C in DP buffer (16.7 mM
Tris-Cl, 167 mM NaCl, 1.1% Triton X-100, 1.2 mM EDTA, and
protease inhibitors) and 20 ml glutathione sepharose 4B (GE
Healthcare) or protein G magnetic Dynabeads (Invitrogen), the
beadswere removed, and the supernatantwas incubated overnight
with the domain (7.5–60 mg) or antibody of interest (following the
manufacturer’s recommendations). On the next day, the domain-
or antibody-chromatin complexes were immobilized on 20 ml
glutathione sepharose 4B (GE Healthcare) or protein G mag-
netic Dynabeads (Invitrogen), respectively. The washing steps of
MPHOSPH8 Chromo, CBX1 Chromo, CBX7 Chromo, and the an-
tibodies were the following: 13 low salt buffer (20 mM Tris-Cl, 150
mMNaCl, 1% Triton X-100, 0.1% SDS, and 2 mM EDTA), 13 high
salt buffer (20 mM Tris-Cl, 500 mM NaCl, 1% Triton X-100, 0.1%
SDS, and 2 mM EDTA), 13 LiCl buffer (10 mM Tris-Cl, 250 mM
LiCl, 1%NP-40, 1%DOC, and 1mMEDTA), and 23 TE buffer. The
washing steps of DNMT3A PWWP and ATRX ADD were less
stringent: 33 PB buffer (50 mM Tris-Cl, 200–400 mMNaCl, 1 mM
EDTA, 0.5% NP-40, 2 mM DTT), 23 TE buffer. Bound chromatin
was eluted in elution buffer (50 mM Tris-Cl, 50 mM NaCl, 1 mM
EDTA, 1% SDS) for 45 min at room temperature with rotation.
DNA was recovered using ChIP DNA purification columns (Active
Motif). The quantitative PCR assays were performed on a CFX96
Touch or CFX96 Real-Time detection system (Bio-Rad) using SYBR
fast qPCR mix (Kapa Biosystems) or SsoFast EvaGreen supermix
(Bio-Rad). A standard curve was generated to calculate percent of
precipitated DNA and test the efficiency of each primer set. The
primer sequences can be found in Supplemental Table S1.
Deep sequencing and data analysis
Approximately 20–50 million 50- or 100-nt sequence reads
obtained with Illumina’s HiSeq 2000/2500 were mapped to the
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human reference genome hg19 with Bowtie (Langmead et al.
2009) from the Chipster software tool (Kallio et al. 2011). Only
uniquely mapped reads were retained and all duplicates were
removed. SICER (Zang et al. 2009) was used for peak calling with
a window size of 200, fragment size of 150, gap size of 1200, and
statistical threshold value of 0.01 (FDR). The genome coverage
files were obtained with BEDTools (Quinlan and Hall 2010) in
Galaxy (Giardine et al. 2005; Blankenberg et al. 2010; Goecks
et al. 2010), and the coverage was normalized by reads permillion
(RPM). The peak annotation was done with CEAS within the
Cistrome platform (Shin et al. 2009; Liu et al. 2011). For over-
lapping pieces of peak regions, we used the common intersection
tool in Galaxy and Cistrome. For peak overlap analyses of
MPHOSPH8 Chromo and anti-H3K9me3 antibodies, only peaks
with a twofold enrichment metric were selected to make the
analysis more reliable. For analyses with ATRX ADD, peaks with
2.75-fold enrichment were used. EpiExplorer (Halachev et al.
2012) was used for annotation of repeats and chromatin seg-
ments (based on data from Ernst et al. 2011), and seqMINER (Ye
et al. 2011) was used for k-means clustering and heatmap gen-
eration. To assess the overall pairwise similarity between domains
and antibodies, we calculated Spearman’s rank correlation co-
efficient in window sizes of 10 or 15 kb with deepTools (Ramirez
et al. 2014). The genome browser snapshots were taken with the
Integrative Genomics Viewer (IGV).
The HepG2 cell line raw sequencing data for all ChIP-
seq experiments (except for H3K9me2, which were carried
out in our lab) were downloaded from ENCODE (http://
hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncode
BroadHistone/).
RNA-seq analysiswas performedwith theTuxedo Suite package
(Trapnell et al. 2012). The reads were mapped with TopHat using
default settings, and the transcripts were assembled with Cufflinks.
After assembly, all transcripts were ranked based on the FPKM
(fragments per kilobase of exon per million fragments mapped)
metric in three groups (highest expression FPKM > 50, medium
expression FPKM 5–15, and lowest expression FPKM < 5). These
transcripts were associated with genes and used as a reference for
metagene analysis of DNMT3A PWWP and the anti-H3K36me3
antibody. In the case of CBX7 Chromo and the anti-H3K27me3
antibody, all UCSC genes, expressed genes from RNA-seq data, and
genes associated with EZH2 peaks were used as a reference for meta-
gene analysis. All genes were fitted in a 5-kb-long metagene with
1-kb regions upstream of and downstream from the TSS and TTS, re-
spectively, and the composite profiles were obtained with deepTools.









CIDOP-seq data for this study have been submitted to the
ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under
accession number E-MTAB-2143. The HMID expression plasmids
have been submitted to AddGene (www.addgene.org; deposit
71277) under plasmid ID numbers 59694–59699.
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